Targeted polymeric nanoparticles for cancer gene therapy

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorKIM, Jayoung
dc.contributor.authorWILSON, David R.
dc.contributor.authorZAMBONI, Camila G.
dc.contributor.authorGREEN, Jordan J.
dc.date.accessioned2016-07-18T12:24:14Z
dc.date.available2016-07-18T12:24:14Z
dc.date.issued2015
dc.description.abstractIn this article, advances in designing polymeric nanoparticles for targeted cancer gene therapy are reviewed. Characterization and evaluation of biomaterials, targeting ligands, and transcriptional elements are each discussed. Advances in biomaterials have driven improvements to nanoparticle stability and tissue targeting, conjugation of ligands to the surface of polymeric nanoparticles enable binding to specific cancer cells, and the design of transcriptional elements has enabled selective DNA expression specific to the cancer cells. Together, these features have improved the performance of polymeric nanoparticles as targeted non-viral gene delivery vectors to treat cancer. As polymeric nanoparticles can be designed to be biodegradable, non-toxic, and to have reduced immunogenicity and tumorigenicity compared to viral platforms, they have significant potential for clinical use. Results of polymeric gene therapy in clinical trials and future directions for the engineering of nanoparticle systems for targeted cancer gene therapy are also presented.
dc.description.indexMEDLINE
dc.description.sponsorshipNIH [1R01EB016721]
dc.description.sponsorshipSamsung
dc.description.sponsorshipNational Science Foundation
dc.description.sponsorshipCAPES-Brazil
dc.identifier.citationJOURNAL OF DRUG TARGETING, v.23, n.7-8, p.627-641, 2015
dc.identifier.doi10.3109/1061186X.2015.1048519
dc.identifier.eissn1029-2330
dc.identifier.issn1061-186X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/14420
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofJournal of Drug Targeting
dc.rightsrestrictedAccess
dc.rights.holderCopyright TAYLOR & FRANCIS LTD
dc.subjectCancer therapy
dc.subjectcell-specificity
dc.subjectgene delivery
dc.subjectnanoparticles
dc.subjectpolymeric biomaterial
dc.subjectpromoter
dc.subjecttargeting ligands
dc.subjecttissue-specificity
dc.subject.othernucleic-acid delivery
dc.subject.otherhepatocellular-carcinoma cells
dc.subject.othermesenchymal stem-cells
dc.subject.othersmall interfering rnas
dc.subject.otherplasmid dna delivery
dc.subject.otherin-vivo
dc.subject.otherbreast-cancer
dc.subject.othersuicide gene
dc.subject.othertransgene expression
dc.subject.otherprostate-cancer
dc.subject.wosPharmacology & Pharmacy
dc.titleTargeted polymeric nanoparticles for cancer gene therapy
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalKIM, Jayoung:Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD USA
hcfmusp.author.externalWILSON, David R.:Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD USA
hcfmusp.author.externalGREEN, Jordan J.:Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, Baltimore, MD USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA
hcfmusp.citation.scopus38
hcfmusp.contributor.author-fmusphcCAMILA GADENS ZAMBONI
hcfmusp.description.beginpage627
hcfmusp.description.endpage641
hcfmusp.description.issue7-8
hcfmusp.description.volume23
hcfmusp.origemWOS
hcfmusp.origem.pubmed26061296
hcfmusp.origem.scopus2-s2.0-84944273483
hcfmusp.origem.wosWOS:000374769200007
hcfmusp.publisher.cityABINGDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceAlberts B., 2002, MOL BIOL CELL
hcfmusp.relation.referenceDATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149
hcfmusp.relation.referenceChen YC, 2010, MOL THER, V18, P1650, DOI 10.1038/mt.2010.136
hcfmusp.relation.referenceSu ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125
hcfmusp.relation.referencePoon Z, 2011, NANO LETT, V11, P2096, DOI 10.1021/nl200636r
hcfmusp.relation.referenceBader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
hcfmusp.relation.referenceFrancis SM, 2014, MOL THER, V22, P1643, DOI 10.1038/mt.2014.24
hcfmusp.relation.referenceKnop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
hcfmusp.relation.referenceJeong GJ, 2007, J CONTROL RELEASE, V118, P118, DOI 10.1016/j.jconrel.2006.12.009
hcfmusp.relation.referenceParr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145
hcfmusp.relation.referenceAbdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947
hcfmusp.relation.referenceYOKOTA J, 1988, ONCOGENE, V2, P283
hcfmusp.relation.referenceLemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81
hcfmusp.relation.referencePeng SF, 2009, BIOMATERIALS, V30, P1797, DOI 10.1016/j.biomaterials.2008.12.019
hcfmusp.relation.referenceBarh D, 2010, CURR ONCOL, V17, P70
hcfmusp.relation.referenceKEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107
hcfmusp.relation.referenceCohen JL, 2011, BIOCONJUGATE CHEM, V22, P1056, DOI 10.1021/bc100542r
hcfmusp.relation.referenceBURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7
hcfmusp.relation.reference[Anonymous], 2000, PROG INFLAM RES
hcfmusp.relation.referenceAshkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637
hcfmusp.relation.referenceMinn I, 2014, ADV CANCER RES, V124, P131, DOI 10.1016/B978-0-12-411638-2.00004-5
hcfmusp.relation.referenceXiong J, 2012, CANCER-AM CANCER SOC, V118, P536, DOI 10.1002/cncr.26289
hcfmusp.relation.referencePetros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
hcfmusp.relation.referenceFields RJ, 2012, J CONTROL RELEASE, V164, P41, DOI 10.1016/j.jconrel.2012.09.020
hcfmusp.relation.referenceZhang LX, 2012, CANCER RES, V72, P4276, DOI 10.1158/0008-5472.CAN-12-1013
hcfmusp.relation.referenceAndo S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687
hcfmusp.relation.referenceMoffatt S, 2006, GENE THER, V13, P761, DOI 10.1038/sj.gt.3302721
hcfmusp.relation.referenceKevil C, 1995, ONCOGENE, V11, P2339
hcfmusp.relation.referenceZheng ZM, 2004, J BIOMED SCI, V11, P278, DOI 10.1159/000077096
hcfmusp.relation.referenceCheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338
hcfmusp.relation.referenceBishop CJ, 2013, J AM CHEM SOC, V135, P6951, DOI 10.1021/ja4002376
hcfmusp.relation.referenceVILE RG, 1993, CANCER RES, V53, P962
hcfmusp.relation.referenceLunsford L, 2000, J DRUG TARGET, V8, P39, DOI 10.3109/10611860009009208
hcfmusp.relation.referencePrabha S, 2004, MOL PHARMACEUT, V1, P211, DOI 10.1021/mp049970+
hcfmusp.relation.referenceTzeng SY, 2013, J BIOMED MATER RES A, V101, P1837, DOI 10.1002/jbm.a.34616
hcfmusp.relation.referencePatel PC, 2010, BIOCONJUGATE CHEM, V21, P2250, DOI 10.1021/bc1002423
hcfmusp.relation.referenceTinsley-Bown AM, 2000, J CONTROL RELEASE, V66, P229, DOI 10.1016/S0168-3659(99)00275-8
hcfmusp.relation.referenceLi Q, 2014, CLIN CANCER RES, V20, P2375, DOI 10.1158/1078-0432.CCR-13-1415
hcfmusp.relation.referenceViola JR, 2010, EXPERT OPIN DRUG DEL, V7, P721, DOI 10.1517/17425241003716810
hcfmusp.relation.referenceDavis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y
hcfmusp.relation.referenceWAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
hcfmusp.relation.referenceDARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315
hcfmusp.relation.referenceAnton M, 2005, CANCER GENE THER, V12, P640, DOI 10.1038/sj.cgt.7700829
hcfmusp.relation.referenceO'Keefe DS, 2000, PROSTATE, V45, P149
hcfmusp.relation.referenceDeFatta RJ, 2002, CANCER GENE THER, V9, P573, DOI 10.1038/sj.cgt.7700468
hcfmusp.relation.referenceWang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250
hcfmusp.relation.referenceMeric F, 2002, MOL CANCER THER, V1, P971
hcfmusp.relation.referenceStruhl K, 1995, ANNU REV GENET, V29, P651
hcfmusp.relation.referenceCooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856
hcfmusp.relation.referenceLee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103
hcfmusp.relation.referenceBlessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488
hcfmusp.relation.referenceZhang C, 2010, BIOMATERIALS, V31, P6075, DOI 10.1016/j.biomaterials.2010.04.042
hcfmusp.relation.referenceHedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
hcfmusp.relation.referenceBhise NS, 2010, BIOMATERIALS, V31, P8088, DOI 10.1016/j.biomaterials.2010.07.023
hcfmusp.relation.referenceMenard S, 2001, ANN ONCOL, V12, P15, DOI 10.1023/A:1011151505425
hcfmusp.relation.referenceHuang YH, 2009, CANCER RES, V69, P6184, DOI 10.1158/0008-5472.CAN-09-0061
hcfmusp.relation.referenceButz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894
hcfmusp.relation.referenceRice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326
hcfmusp.relation.referenceZhou JB, 2012, NAT MATER, V11, P82, DOI [10.1038/nmat3187, 10.1038/NMAT3187]
hcfmusp.relation.referenceIto T, 2010, BIOMATERIALS, V31, P2912, DOI 10.1016/j.biomaterials.2009.12.032
hcfmusp.relation.referenceGuerrero-Cazares H, 2014, ACS NANO, V8, P5141, DOI 10.1021/nn501197v
hcfmusp.relation.referenceTuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.3.CO;2-I
hcfmusp.relation.referenceChithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
hcfmusp.relation.referenceGoverdhana S, 2005, MOL THER, V12, P189, DOI 10.1016/j.ymthe.2005.03.022
hcfmusp.relation.referenceGao P, 2008, CANCER SCI, V99, P2209, DOI 10.1111/j.1349-7006.2008.00941.x
hcfmusp.relation.referenceChang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
hcfmusp.relation.referenceCohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
hcfmusp.relation.referenceZeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100
hcfmusp.relation.referenceSong J, 2004, CANCER RES, V64, P7661, DOI 10.1158/0008-5472.CAN-04-1751
hcfmusp.relation.referenceGreen JJ, 2007, NANO LETT, V7, P874, DOI 10.1021/nl062395b
hcfmusp.relation.referenceKircheis R, 1997, GENE THER, V4, P409, DOI 10.1038/sj.gt.3300418
hcfmusp.relation.referenceYin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
hcfmusp.relation.referenceOhno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
hcfmusp.relation.referenceWAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255
hcfmusp.relation.referencePan CX, 1999, MED HYPOTHESES, V53, P130, DOI 10.1054/mehy.1998.0731
hcfmusp.relation.referenceRojanarata T, 2008, PHARM RES-DORD, V25, P2807, DOI 10.1007/s11095-008-9648-6
hcfmusp.relation.referenceNettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2
hcfmusp.relation.referenceHanna N, 2012, CANCER GENE THER, V19, P374, DOI 10.1038/cgt.2012.10
hcfmusp.relation.referenceNeedham CJ, 2012, BIOMACROMOLECULES, V13, P1429, DOI 10.1021/bm300145q
hcfmusp.relation.referenceMaston GA, 2006, ANNU REV GENOM HUM G, V7, P29, DOI 10.1146/annurev.genom.7.080505.115623
hcfmusp.relation.referenceWang DQ, 1999, J CONTROL RELEASE, V57, P9, DOI 10.1016/S0168-3659(98)00099-6
hcfmusp.relation.referenceMOCHIZUKI H, 1992, MOL CARCINOGEN, V6, P83, DOI 10.1002/mc.2940060203
hcfmusp.relation.referenceAboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846
hcfmusp.relation.referenceMastorakos P, 2015, NANOSCALE, V7, P3845, DOI 10.1039/c4nr04284k
hcfmusp.relation.referenceSu ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102
hcfmusp.relation.referencePiccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
hcfmusp.relation.referenceROSS JF, 1994, CANCER, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
hcfmusp.relation.referenceHarris TJ, 2010, BIOMATERIALS, V31, P998, DOI 10.1016/j.biomaterials.2009.10.012
hcfmusp.relation.referenceChen J, 2009, BIOMACROMOLECULES, V10, P2921, DOI 10.1021/bm900724c
hcfmusp.relation.referenceGrzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6
hcfmusp.relation.referencePapadakis ED, 2004, CURR GENE THER, V4, P89, DOI 10.2174/1566523044578077
hcfmusp.relation.referenceBazzoni F, 2001, CANCER RES, V61, P1050
hcfmusp.relation.referenceKhan JA, 2007, CHEMBIOCHEM, V8, P1237, DOI 10.1002/cbic.200700165
hcfmusp.relation.referenceBellocq NC, 2003, BIOCONJUGATE CHEM, V14, P1122, DOI 10.1021/bc034125f
hcfmusp.relation.referenceHarris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
hcfmusp.relation.referenceSakae M, 2008, BIOMED PHARMACOTHER, V62, P448, DOI 10.1016/j.biopha.2007.12.009
hcfmusp.relation.referenceHildebrandt IJ, 2003, GENE THER, V10, P758, DOI 10.1038/sj.gt.3301939
hcfmusp.relation.referenceOgris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
hcfmusp.relation.referenceDutta D, 2007, TOXICOL SCI, V100, P303, DOI 10.1093/toxsci/kfm217
hcfmusp.relation.referenceLee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/nnano.2012.73, 10.1038/NNANO.2012.73]
hcfmusp.relation.referenceLi JJ, 2013, CHEM COMMUN, V49, P6974, DOI 10.1039/c3cc43576h
hcfmusp.relation.referenceHayes GM, 2002, CANCER GENE THER, V9, P133, DOI 10.1038/sj.cgt.7700427
hcfmusp.relation.referenceHarrington KJ, 2000, ADV DRUG DELIVER REV, V44, P167, DOI 10.1016/S0169-409X(00)00093-4
hcfmusp.relation.referenceBateman BT, 2001, INFECT IMMUN, V69, P7851, DOI 10.1128/IAI.69.12.7851-7857.2001
hcfmusp.relation.referenceCrew JP, 2000, BRIT J CANCER, V82, P161
hcfmusp.relation.referenceLee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77
hcfmusp.relation.referenceWAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410
hcfmusp.relation.referenceDevi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
hcfmusp.relation.referenceRobson T, 2003, J BIOMED BIOTECHNOL, P110
hcfmusp.relation.referenceAmbrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177
hcfmusp.relation.referenceJones HE, 2006, ENDOCR-RELAT CANCER, V13, pS45, DOI 10.1677/erc.1.01275
hcfmusp.relation.referenceCohen JA, 2010, ADV MATER, V22, P3593, DOI 10.1002/adma.201000307
hcfmusp.relation.referenceBayele HK, 2005, J PHARM SCI-US, V94, P446, DOI 10.1002/jps.20230
hcfmusp.relation.referenceDelmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107
hcfmusp.relation.referenceGallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229
hcfmusp.relation.referenceDas B, 2004, P NATL ACAD SCI USA, V101, P4839, DOI 10.1073/pnas.0401011101
hcfmusp.relation.referenceBoylan NJ, 2012, J CONTROL RELEASE, V157, P72, DOI 10.1016/j.jconrel.2011.08.031
hcfmusp.relation.referenceStudeny M, 2002, CANCER RES, V62, P3603
hcfmusp.relation.referenceHsu YY, 1999, J DRUG TARGET, V7, P313
hcfmusp.relation.referenceKnapinska AM, 2005, CURR GENOMICS, V6, P471, DOI 10.2174/138920205774482954
hcfmusp.relation.referenceMao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8
hcfmusp.relation.referenceWang R, 2009, LUNG CANCER, V66, P237, DOI 10.1016/j.lungcan.2009.02.001
hcfmusp.relation.referenceGUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L
hcfmusp.relation.referenceYadav S, 2009, CANCER CHEMOTH PHARM, V63, P711, DOI 10.1007/s00280-008-0790-y
hcfmusp.relation.referenceLi N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035
hcfmusp.relation.referenceBenoit MA, 2001, J DRUG TARGET, V9, P253
hcfmusp.relation.referenceWalter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168-3659(01)00413-8
hcfmusp.relation.referenceLombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005
hcfmusp.relation.referenceDanhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
hcfmusp.relation.referenceHan SE, 2009, J DRUG TARGET, V17, P123, DOI 10.1080/10611860802472461
hcfmusp.relation.referenceAkar U, 2008, AUTOPHAGY, V4, P669
hcfmusp.relation.referenceMeyer M, 2009, MOL PHARMACEUT, V6, P752, DOI 10.1021/mp9000124
hcfmusp.relation.referenceGu JJ, 2012, BIOMATERIALS, V33, P644, DOI 10.1016/j.biomaterials.2011.09.076
hcfmusp.relation.referencePANG S, 1995, HUM GENE THER, V6, P1417, DOI 10.1089/hum.1995.6.11-1417
hcfmusp.relation.referenceKurosaki T, 2009, BIOMATERIALS, V30, P2846, DOI 10.1016/j.biomaterials.2009.01.055
hcfmusp.relation.referenceRoth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55
hcfmusp.relation.referenceSchaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G
hcfmusp.relation.referenceBuscail L, 2015, MOL THER, V23, P779, DOI 10.1038/mt.2015.1
hcfmusp.relation.referenceWalczak H, 1999, NAT MED, V5, P157
hcfmusp.relation.referenceAmbrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
hcfmusp.relation.referenceTorchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
hcfmusp.relation.referenceChoi KY, 2012, BIOMATERIALS, V33, P6186, DOI 10.1016/j.biomaterials.2012.05.029
hcfmusp.relation.referenceChiu SH, 2004, J CONTROL RELEASE, V97, P357, DOI 10.1016/j.jconrel.2004.03.019
hcfmusp.relation.referenceShmueli RB, 2012, NANOMED-NANOTECHNOL, V8, P1200, DOI 10.1016/j.nano.2012.01.006
hcfmusp.relation.referenceDavis ME, 2004, CURR MED CHEM, V11, P179, DOI 10.2174/0929867043456179
hcfmusp.relation.referenceZhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698
hcfmusp.relation.referenceManome Y, 1998, HUM GENE THER, V9, P1409, DOI 10.1089/hum.1998.9.10-1409
hcfmusp.relation.referenceAkinc A, 2010, MOL THER, V18, P1357, DOI 10.1038/mt.2010.85
hcfmusp.relation.referenceBOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
hcfmusp.relation.referenceHu BG, 2014, EXP CELL RES, V324, P183, DOI 10.1016/j.yexcr.2014.04.005
hcfmusp.relation.referenceJafari M, 2012, CURR MED CHEM, V19, P197
hcfmusp.relation.referenceAdryan B, 2007, FLY, V1, P142
hcfmusp.relation.referenceSestakova B, 2006, FOLIA BIOL-PRAGUE, V52, P161
hcfmusp.relation.referenceVerma A, 2010, SMALL, V6, P12, DOI 10.1002/smll.200901158
hcfmusp.relation.referenceForrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g
hcfmusp.relation.referenceWang Z, 2011, PHARM RES-DORDR, V28, P2983, DOI 10.1007/s11095-011-0604-5
hcfmusp.relation.referenceAlvarez RD, 2014, GYNECOL ONCOL, V133, P433, DOI 10.1016/j.ygyno.2014.03.571
hcfmusp.relation.referenceHuang RQ, 2007, FASEB J, V21, P1117, DOI 10.1096/fj.06-7380com
hcfmusp.relation.referenceOgris M, 2003, J CONTROL RELEASE, V91, P173, DOI 10.1016/S0168-3659(03)00230-X
hcfmusp.relation.referenceDavis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
hcfmusp.relation.referenceKawashita Y, 1999, HUM GENE THER, V10, P1509, DOI 10.1089/10430349950017842
hcfmusp.relation.referenceKunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
hcfmusp.relation.referencevan Vlerken LE, 2007, PHARM RES, V24, P1405, DOI 10.1007/s11095-007-9284-6
hcfmusp.relation.referenceFarnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
hcfmusp.relation.referenceBivas-Benita M, 2004, EUR J PHARM BIOPHARM, V58, P1, DOI 10.1016/j.ejpb.2004.03.008
hcfmusp.relation.referencePack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
hcfmusp.relation.referenceKOROMILAS AE, 1992, EMBO J, V11, P4153
hcfmusp.relation.referenceKomarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535-7163.MCT-05-0334
hcfmusp.relation.referenceJaggar RT, 1997, HUM GENE THER, V8, P2239, DOI 10.1089/hum.1997.8.18-2239
hcfmusp.relation.referenceLabhasetwar V, 1998, J PHARM SCI, V87, P1347, DOI 10.1021/js980077+
hcfmusp.relation.referenceSmith-Arica JR, 2000, MOL THER, V2, P579, DOI 10.1006/mthe.2000.0215
hcfmusp.relation.referenceHARRIS JD, 1994, GENE THER, V1, P170
hcfmusp.relation.referenceKlutz K, 2011, MOL THER, V19, P676, DOI 10.1038/mt.2010.296
hcfmusp.relation.referenceBhatia Shilpa, 2013, Discov Med, V15, P309
hcfmusp.relation.referenceBhatnagar A, 2014, CANCER RES, V74, P5772, DOI 10.1158/0008-5472.CAN-14-0018
hcfmusp.relation.referenceBuchholz DR, 2012, XENOPUS PROTOCOL POS, P265
hcfmusp.relation.referenceCarlberg C, 2014, TRANSCRIPTION FACTOR, P55
hcfmusp.relation.referenceChen JQ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-15
hcfmusp.relation.referenceHyo-eun CB, 2011, NAT MED, V17, P123
hcfmusp.relation.referenceKim J, 2014, BIOCONJUGATE CHEM, V25, P43, DOI 10.1021/bc4002322
hcfmusp.relation.referencePecot CV, 2014, MOL CANCER THER, V13, P2876, DOI 10.1158/1535-7163.MCT-14-0074
hcfmusp.relation.referenceSLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
hcfmusp.relation.referenceUrban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
hcfmusp.relation.referenceVoellmy R, 2011, J GENET SYNDR GENE T, V2, P107
hcfmusp.relation.referenceWelch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293
hcfmusp.relation.referenceYao YD, 2012, SCI TRANSL MED, V4, P130, DOI 10.1126/SCITRANSLMED.3003601
hcfmusp.relation.referenceZarogoulidis P, 2013, J GENET SYNDR GENE T, V4, P1
hcfmusp.relation.referenceZhao XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056395
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublicationeb51883b-2d52-4ef6-8118-b24a526560b6
relation.isAuthorOfPublication.latestForDiscoveryeb51883b-2d52-4ef6-8118-b24a526560b6
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_KIM_Targeted_polymeric_nanoparticles_for_cancer_gene_therapy_2015.PDF
Tamanho:
2.31 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - ODS/03